[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 23, 1995

The Utility of Prostate-Specific Antigen for Detecting Prostate Cancer

Author Affiliations

University of Pennsylvania Philadelphia

JAMA. 1995;274(8):607. doi:10.1001/jama.1995.03530080023019

To the Editor.  —The recent article by Dr Gann and colleagues1 assesses the utility of random screening using prostate-specific antigen (PSA) for the detection of prostate cancer. The authors conclude that the use of a single PSA measurement is "highly informative." They evaluated their data using sensitivities (defined as the percentage of prostate cancer cases testing positive for PSA) and specificities (defined as the percentage of prostate cancer—free controls testing negative for PSA). However, sensitivity and specificity values, by themselves, do not determine the usefulness of a diagnostic test. Rather, usefulness is better determined by evaluating positive predictive values (PPVs) and negative predictive values (NPVs).2The PPV of a test is the probability that a person with an elevated test value has the disorder in question. Unlike sensitivity and specificity values, PPVs vary depending on the prevalence of the disease in the population. This dependence becomes particularly important

First Page Preview View Large
First page PDF preview
First page PDF preview